Oral pharmacotherapy for the movement disorders of cerebral palsy

Journal of Child Neurology

Volumn 11, Issue SUPPL. 1, 1996, Pages

  Pranzatelli, Michael R ^a,b  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b National Pediatric Myoclonus Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ADRENERGIC RECEPTOR STIMULATING AGENT; AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ANTIPARKINSON AGENT; BACLOFEN; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CARBIDOPA PLUS LEVODOPA; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOMIPRAMINE; CLONAZEPAM; DANTROLENE; DIAZEPAM; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; FLUOXETINE; FLUPHENAZINE; HALOPERIDOL; IMIPRAMINE; LORAZEPAM; PHENOBARBITAL; PIMOZIDE; PRIMIDONE; TETRABENAZINE; TRIHEXYPHENIDYL; UNINDEXED DRUG; VALPROIC ACID;

ARTICLE; CEREBRAL PALSY; CHOREOATHETOSIS; DROWSINESS; DRUG INDUCED DISEASE; DYSTONIA; EPILEPSY; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; HUMAN; HYPERKINESIA; MOTOR DYSFUNCTION; MUSCLE WEAKNESS; MYOCLONUS; PRIORITY JOURNAL; RASH; SPASTICITY; VERTIGO;

EID: 0029956662     PISSN: 08830738     EISSN: None     Source Type: Journal    
DOI: 10.1177/0883073896011001s03     Document Type: Article

References (102)

1. Holt KS: The treatment of spasticity in children. Postgrad Med J 1972;48(Suppl):41.
2. Crothers B, Paine RS: The Natural History of Cerebral Palsy. Cambridge, MA, Harvard University Press, 1959.
3. Candy EJ, Hoon AH, Capute AJ, Bryan RN: MRI in motor delay: Important adjunct to classification of cerebral palsy. Pediatr Neurol 1993;9:421-429.
4. Foley J: Dyskinetic and dystonic cerebral palsy and birth. Acta Paediatr 1992;81:57-60.
5. Pranzatelli MR: Update on pediatric movement disorders. Adv Pediatr 1995;42:415-463.
6. Thompson GH, Rubin IL, Bilenker RM: Comprehensive Management of Cerebral Palsy. New York, Grune & Stratton, 1983, p106.
7. Hagberg B, Hagberg G, Olow I: The changing panorama of cerebral palsy in Sweden 1954-1970. Acta Paediatr Scand 1975;64: 193-200.
8. Polani PE: The natural history of choreoathetoid cerebral palsy. Guy Hosp Rep 1959;108:32.
9. Pranzatelli MR: Advances in the treatment of pediatric movement disorders. Int Pediatr 1995;10:250-259.
10. Pranzatelli MR: Antidyskinetic drug therapy for pediatric movement disorders. J Child Neurol 1996;11:355-369.
11. Fahn S, Jankovic J: Practical management of dystonia. Neurol Clin 1984;2:555-569.
12. Jankovic J, Orman J: Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias. Neurology 1988;38:391-394.
13. Falmi YP, Zohar Y, Finkelstein Y, Laurian N: Reduction of salivary flow with Scopoderm TTS. Ann Otol Rhinol Laryngol 1988;97: 128-130.
14. Reddihough D, Johnson H, Staples M, et al: Use of benzhexol hydrochloride to control drooling of children with cerebral palsy. Dev Med Child Neurol 1990;32:985-989.
15. Siegel LK, Klingbeil MA: Control of drooling with transdermal scopolamine in a child with cerebral palsy. Dev Med Child Neurol 1991;33:1013-1014.
16. Greene P: Review. Baclofen in the treatment of dystonia. Clin Neuropharmacol 1992;15:276-288.
17. Chapman AG: Valproate and myoclonus. Adv Neurol 1986;43: 661-674.
18. Pranzatelli MR: Myoclonic disorders. Pediatr Ann 1993;22:33-37.
19. Pranzatelli MR, Nadi NS: Mechanism of action of antiepileptic and antimyoclonic drugs. Adv Neurol 1995;67:329-360.
20. B, receptor agonists and antagonists. Clin Neuropharmacol 1995;18:285-305.
21. Obeso JA, Artieda J, Quinn N, et al: Piracetam in the treatment of different types of myoclonus. Clin Neuropharmacol 1988;11:529-536.
22. Gouliaev AH, Senning A: Piracetam and other structurally related nootropics. Brain Res Brain Res Rev 1994;19:180-222.
23. Pranzatelli MR: Serotonin and human myoclonus: Rationale for the use of serotonin receptor agonists and antagonists. Arch Neurol 1994;51:605-617.
24. Foley J: The athetoid syndrome: A review of a personal series. J Neurol Neurosurg Psychiatry 1983;46:289-298.
25. Klawans HL, Brandabur MM: Chorea in childhood. Pediatr Ann 1993;22:41-52.
26. Cook JB, Nathan PW: On the site of action of diazepam in spasticity in man. J Neurol Sci 1967;5:33-37.
27. Brodgen RN, Speight TM, Avery GS: Baclofen: A preliminary report of its pharmacological properties and therapeutic efficacy in spasticity. Drugs 1974;8:1-4.
28. Denhoff E, Holden RH: Relaxant drugs in cerebral palsy. N Engl J Med 1961;264:475-480.
29. Davidoff RA: Antispasticity drugs: Mechanism of action. Ann Neurol 1985;17:107-116.
30. Dahlin M, Knutsson E, Nergardh A: Treatment of spasticity in children with low dose benzodiazepine. J Neurol Sci 1993;117:54-60.
31. Yablon SA, Sipski ML: Effect of transdermal clonidine on spinal spasticity. A case series. Am J Phys Med Rehabil 1993;72:154-157.
32. Young RR: Spasticity: A review. Neurology 1994;44(Suppl 9):S12-S20.
33. Denhoff E: Cerebral palsy - a pharmacologie approach. Clin Pharmacol Ther 1964;5:947-954.
34. Engle HA: The effect of diazeparn (Valium) in children with cerebral palsy: A double-blind study. Dev Med Child Neurol 1966;8: 661-667.
35. Nogen AG: Effect of dantrolene sodium on the incidence of seizures in children with spasticity. Childs Brain 1979;5:420-425.
36. Hiller CJ, Mason JL: Therapeutic test of diazepam (Valium) in cerebral palsy. J S C Med Assoc 1966;62:306-309.
37. Holt KS: The use diazepam in childhood cerebral palsy. Report of a small study including electromyographic observations. Ann Phys Med 1964;Suppl:16-24.
38. Carter CH: Evaluation of diazepam in skeletal muscle hypertonicity in cerebral palsy. Arch Phys Med Rehabil 1968;49:519-523.
39. Kanjilal GC: Some observations on clinical trials with diazepam in cerebral palsy. Ann Phys Med 1964;Suppl:30-32.
40. Phelps WM: Observation of a new drug in cerebral palsy athetoids. Symposium on diazepam. West Med 1963;4:5-10.
41. Marsh HO: Diazepam in incapacitated cerebral-palsied children. JAMA 1965;191:797-800.
42. Milla PJ, Jackson ADM: A controlled trial of baclofen in children with cerebral palsy. J Int Med Res 1977;5:398-404.
43. Calta RG, Sautomauro ET. The use of baclofen in children with cerebral palsy. Folia Med (Plovdiv) 1976;73:199-201.
44. Knutsson E, Lindblom U, Martensson A: Plasma and cerebrospinal fluid levels of baclofen (Lioresal) at optimal therapeutic responses in spastic paresis. J Neurol Sci 1974;23:473-484.
45. Burke RE, Fahn S, Marsden CD: Torsion dystonia: A double-blind, prospective trial of high-dosage trihexyphenidyl. Neurology 1986;36:160-164.
46. Fahn S: High dosage anticholinergic therapy in dystonia. Neurology 1983;33:1255-1261.
47. Pinder RM, Brogden RN, Speight TM, Avery GS: Dantrolene sodium: A review of its pharmacological properties and therapeutic efficacy in spasticity. Drugs 1977;13:3-23.
48. Joynt RL, Leonard JA: Dantrolene sodium suspension in treatment of spastic cerebral palsy. Dev Med Child Neurol 1980;22:755-767.
49. Ford F, Bleck EE, Aptekar RG, et al: Efficacy of dantrolene sodium in the treatment of spastic cerebral palsy. Dev Med Child Neurol 1976;18:770-783.
50. Denhoff E, Feldman S, Smith MG, et al: .Treatment of spastic cerebral-palsied children with sodium dantrolene. Dev Med Cliild Neurol 1975;17:736-742.
51. Haslam RHA, Walcher JR, Leitman PS, et al: Dantrolene sodium in children with spasticity. Arch Phys Med Reliabil 1974;55:384-388.
52. Chyatte SB, Birdsong JH, Roberson DL: Dantrolene sodium in athetoid cerebral palsy. Arch Phys Med Rehabil 1973;54:365-368.
53. Heggarty H, Wright T. Tetrabenazine in athetoid cerebral palsy. Dev Med Child Neurol 1974;16:137-142.
54. Maritz NG, Müller FO, Pompa Van Meerdervoort HF: Piracetam in the management of spasticity in cerebral palsy. S Afr Med J 1978;53:889-891.
55. Van Woert MH, Sethy MI: Therapy of intention myoclonus with L-5-hydroxytryptophan and a peripheral decarboxylase inhibitor, MK 486. Neurology 1975;25:135-140.
56. Papini M, Martinetti MG, Pasquinelli A: Trazodone for symptomatic extrapyramidal, disorders of infancy and childhood. Ital J Neurol Sci 1982;3:161-162.
57. Rosenthal RK, McDowell FH, Cooper W: Levodopa therapy in athetoid cerebral palsy. A preliminary report. Neurology 1972;22:1-11.
58. Griffiths MI, Bowie EM: The use of dimethothiazine in the treatment of childhood cerebral palsy. Dev Med Child Neurol 1973;15:25-32.
59. Charash LI, Cooper W: Experience with meprobamate in cerebral palsy. Pediatrics 1958;21:605-608.
60. Katz BE: Education of cerebral palsied children; the role of meprobamate: A preliminary evaluation. J Pediatr 1958;53:467-475.
61. Bjerre I, Blennow G: Methocarbamol in the treatment of cerebral palsy in children. Neuropadiatrie 1971;3:140-146.
62. Denhoff E, Bradley C: Curare treatment of spastic children: Preliminary report. N Engl J Med 1942;226:411-416.
63. Clarke CA, Hotston RD: Curare in oil in the treatment of spastic conditions. BMJ 1948;1:289-291.
64. Denhoff E, Holden RII, Silver CM: Evaluation of Tolserol in the treatment of children with cerebral palsy. N Engl J Med 1949;241:695-698.
65. Perlstein MA, Barnett HE: Neostigmine therapy in cerebral palsy. JAMA 1950;142:403-407.
66. Nygaard TG, Waran SP, Levine RA, et al: Dopa-responsive dystonia simulating cerebral palsy. Pediatr Neurol 1994;11:236-240.
67. Jankovic J: Tardive syndromes and other drug-induced movement disorders. Clin Neuropharmacol 1995;18:197-214.
68. Malamud N: Status marmoratus: A form of cerebral palsy following either birth injury or inflammation of the central nervous system. J Pediatr 1950;37:610-619.
69. Carpenter MB: Status marmoratus of the thalamus and striatum associated with athetosis and dystonia. Neurology 1955;5:139-146
70. Towbin A: The Pathology of Cerebral Palsy. Springfield, IL, Charles C. Thomas, 1960.
71. Yokochi K, Aiba K, Kodama M, Fujtmoto S: Magnetic resonance imaging in athetotic cerebral palsied children. Acta Paediatr Scand 1991;80:818-823.
72. Kyllerman M, Boger B, Bensch K, et al: Dyskinetic cerebral palsy. I: Clinical categories, associated neurological abnormalities and incidences. Acta Paediatr Scand 1982;71:543-550.
73. Brun A, Kyllerman M: Clinical, pathogenetic and neuropathological correlates of dystonic cerebral palsy. Eur J Pediatr 1979;131:83-104.
74. Bhatia KP, Marsden CD: The behavioral and motor consequences of focal lesions of the basal ganglia in man. Brain 1994;117:859-876.
75. Albin RL, Young AB, Penney JB: The functional anatomy of basal ganglia disorders. Trends Neurosci 1989;12:366-375.
76. DeLong MR: Primary models of movement disorders of basal ganglia origin. Trends Neurosci 1990;13:281-285.
77. Denny-Brown D: Diseases of the Basal Ganglia and Subthalamic Nuclei. New York, Oxford University Press, 1946, pp 302.
78. Afifi AK: Basal ganglia: Functional anatomy and physiology. Part 1. J Child Neurol 1994;9:249-260.
79. Afifi AK: Basal ganglia: Functional anatomy and physiology. Part 2. J Child Neurol 1994;9:352-361.
80. Gerfen CR: Dopamine receptor function in the basal ganglia. Clin Neuropharmacol 1995;18(Suppl 1):S162-S177.
81. Greenamyre JT, Porter RHP: Anatomy and physiology of glutamate in the CNS. Neurology 1994;44(Suppl 8):S7-S13.
82. Meador-Woodruff JH: Neuroanatomy of dopamine receptor gene expression: Potential substrates for neuropsychiatric illness. Clin Neuropharmacol 1995;18(Suppl):S14-S24.
83. Rice JE, Vannucci RC, Brierley JB: The influence of immaturity on hypoxic-ischemic brain damage in the rat. Ann Neurol 1981;9:131-141.
84. Johnston MV: Neurotransmitter alteration in a model of perinatal-hypoxic brain injury. Ann Neurol 1983;13:511-518.
85. Burke RE, Karanas AL: Quantitative morphological analysis of striatal cholinergic neurons in perinatal asphyxia. Ann Neurol 1990;27:81-88.
86. Lipton SA, Rosenberg RA: Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med 1994;330:613-622.
87. Meldrum BS: The role of glutamate in epilepsy and other CNS disorders. Neurology 1994;44(Suppl 8):S14-S23.
88. Carlsson A: Towards anew understanding of dopamine receptors. Clin Neuropharmacol 1995;18(Suppl 1):S6-S13.
89. 2 receptor. Clin Neuropharmacol 1995;18(Suppl 1):S130-S142.
90. Palmer GC, Murray RJ, Wilson TCM, et al: Biological profile of the metabolites and potential metabolites of the anticonvulsant remacemide. Epilepsy Res 1992;12:9-20.
91. Fagg GE, Olpe HR, Schmutz M, et al: CGP 37849 and CGP 39551. Novel competitive N-methyl-D-aspartate receptor antagonists with potent anticonvulsant activity, in Meldrum B (ed): Current and Future Trends in Anticonvulsant Therapy. New York, Wiley-Liss, 1990, pp 421-427.
92. 125I-ifenprodil: Synthesis and characterization of binding to a polyamine-sensitive site in cerebral cortical membranes. J Neurochem 1993;61:120-126.
93. Kemp JA, Foster AC, Leeson PD, et al: 7-Chlorokynurenic acid is a selective antagonist at the glycine modulatory site of the N-methyl-D-aspartate receptor complex. Proc Natl Acad Sci USA 1988;85: 6547-6551.
94. Donovan SD, Rogawski MA: GYKI 52466, a 2,3-benzodiazepine, is a highly selective, noncompetitive antagonist of AMPA/kainate receptor responses. Neuron 1993;10:51-59.
95. Leach MJ, Marden CM, Miller AA: Pharmacological studies on lamotrigine, a novel potential antiepileptic drug. II. Neurochemical studies on the mechanism of action. Epilepsia 1986;27:490-497.
96. A receptor channels. Annu Rev Neurosci 1994;17:569-602.
97. Tumble MR, Robertson MM: Clobazam, in Meldrum BS, Porter RJ (eds): New Anticonvulsant Drugs. London, John Libbey, 1986, pp 65-85.
98. B receptor pharmacology. Annu Rev Pharmacol Toxicol 1993;33:109-147.
99. Leppik IE, Graves N, Devinsky O: New antiepileptic medications. Neurol Clin 1993;11:923-949.
100. Metcalf BW, Sjoerdsma A: Suicide inhibition of GABA transaminase, in Singer T, Ondarza PN (eds): Molecular Basis of Drug Action. Amsterdam, Elsevier, 1981, pp 119-131.
101. Nielsen EB, Wolftbrandt KH, Andersen KE, et al: N0-05-0328: A new potent GABA-uptake inhibitor, abstract. Soc Neurosci 1987;13:968.
102. Löscher W, Honack D, Taylor CP: GABApentin increases amino-oxyacetic acid-induced GABA accumulation in different regions of rat brain. Neurosci Lett 1991;128:150-154.